The Global Non-Steroidal Anti-inflammatory Drugs Market size is expected to reach $25.5 billion by 2028, rising at a market growth of 5.7% CAGR during the forecast period

·10 min read
ReportLinker
ReportLinker

Non-steroidal anti-inflammatory medications (NSAIDs) are used to alleviate pain, lower fevers, and improve blood circulation. Furthermore, the inflammation is decreased when high dosages of non-steroidal anti-inflammatory medicines (NSAIDs) are given.

New York, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Non-steroidal Anti-inflammatory Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Distribution Channel, By Route of Disease Indication, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06315035/?utm_source=GNW
Non-steroidal medications have sedative and anti-inflammatory effects. Inflammation is caused by the COX-1 and COX-2 enzymes that are inhibited by non-steroidal anti-inflammatory medications (NSAIDs). Aspirin, naproxen, ibuprofen, and paracetamol are examples of typical non-steroidal anti-inflammatory medications.

The market for non-steroidal anti-inflammatory medications (NSAIDs) is expanding as a result of a number of causes, including the growing incidence of chronic pain worldwide and an ageing population. The expanding use of NSAIDs for headache, toothache, migraine, and menstrual pain, as well as growing preference for OTC NSAIDs, are also anticipated to contribute to the growth over the forecast period. Additionally, the accessibility of a wide range of NSAID products as well as an increase in product approvals and launches are projected to fuel growth over the forecast period.

During the projected period, the prevalence of chronic pain is anticipated to increase, driving NSAID market growth. For instance, the CDC estimates that in the United States, about 20,4% of adults experienced chronic pain in 2019. Age-related increases in the prevalence of chronic pain were most pronounced in persons 65 years of age and older. Compared to Hispanic, non-Hispanic Asian, and non-Hispanic black individuals, non-Hispanic whites had the highest prevalence of chronic pain. About 23.6 percent of non-Hispanic white adults suffer from chronic discomfort. Therefore, given that both COX-2 selective and non-selective NSAIDs are frequently employed in the management of chronic pain, the increasing prevalence of chronic pain is anticipated to promote growth.

COVID-19 Impact Analysis

The infectious disease COVID-19 first surfaced in late December in the Chinese city of Wuhan’s Hubei province. SARS-CoV-2, the virus that causes the acute respiratory syndrome is extremely contagious and spreads from person to person. The virus has spread to 213 nations since its outbreak in December 2019, prompting the World Health Organization to classify it as a pandemic. Governments and pharmaceutical and biotech businesses from all around the world are collaborating to combat the COVID-19 outbreak, from managing the medical supply chain to assisting in the creation of vaccinations. As a result, the demand for the COVID-19 vaccination and its treatment medications is predicted to propel the pharmaceutical and biotechnology sectors forward.

Market Growth Factors

Growing Incidence Of Chronic Pain

Pain that persists for more than 12 weeks without medication or treatment is referred to as chronic or persistent pain. Several people recover from pain due to injuries or operation and return to normalcy. However, there are situations when the pain lasts longer or appears suddenly without any prior history of an accident or surgery. One of the key factors propelling the market expansion for non-steroidal anti-inflammatory medications is the rising prevalence of disorders that cause pain and inflammation. These medications are being used more frequently to treat both acute & chronic pain. Ibuprofen & diclofenac are two medications that are frequently recommended to treat pain.

Increasing Preference Of People For Nsaids Over Opioids

The most often recommended medications for the management of mild to severe pain are NSAIDs and opioids. Opioid use, however, is linked to serious adverse outcomes. Since the dawn of civilization thousands of years ago, opioids have been used to relieve pain. Opioid analgesics are frequently used to treat dull, ill-localized pain, typically abdominal pain. Frequent doses may result in drug tolerance and dependency, and abruptly stopping an opioid painkiller may trigger a withdrawal crisis. Non-opioid, non-steroidal anti-inflammatory medicines (NSAIDs), which do not include opioids, are the most often prescribed analgesics for the management of pain. At larger doses, these medications also have antipyretic, analgesics, and anti-inflammatory properties.

Market Restraining Factors

Adverse Effects Of Nsaids Would Restrict Its Consumption

The market growth is anticipated to be constrained by adverse reactions to NSAID use, including allergic reactions, stomach pain, stomach ulcers, and dizziness. These pharmaceuticals are one of the most often prescribed medicines due to their widespread accessibility and anti-inflammatory effects. However, NSAID-related gastrointestinal issues are on the rise significantly globally, which could put a strain on the healthcare system. The most frequent reason for the most of emergency hospital admissions is GI bleeding related to NSAIDs. Additionally, its side effect is the most typical drug side in the United States.

Disease Indication Outlook

Based on disease indication, the Non-steroidal Anti-inflammatory Drugs Market is segmented into Arthritis, Migraine, Ophthalmic Diseases and Others. The arthritis segment acquired the highest revenue share in the Non-steroidal Anti-inflammatory Drugs Market in 2021. The overall incidence of arthritis & osteoarthritis, the growing senior population worldwide, the strong prescription rate for NSAIDs, and the rise in popularity of topical arthritis treatments are all contributing factors to the segment’s growth.

Route of Administration Outlook

By Route of Administration, the Non-steroidal Anti-inflammatory Drugs Market is classified into Oral, Topical and Others. The oral segment garnered the maximum revenue share in the Non-steroidal Anti-inflammatory Drugs Market in 2021. It is due to the abundance of oral NSAIDs available for treating pain, headaches, fever, and migraines as well as the rise in OTC NSAID sales. To treat headaches and migraines, Johnson & Johnson Consumer Inc. provides their NSAID medication Motrin (ibuprofen), which is offered in dose forms such a tablet, liquid gel, capsule, and solution.



Distribution Channel Outlook

On the basis of distribution channel, the Non-steroidal Anti-inflammatory Drugs Market is divided into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. The hospital pharmacy segment acquired a significant revenue share in the Non-steroidal Anti-inflammatory Drugs Market in 2021. It is because non-steroidal anti-inflammatory medications are widely used to treat pain in hospitalized patients. Along with that, the rise in the number of hospitals across various nations of the world would escalate the growth of the segment over the forecast period.

Regional Outlook

Region-wise, the Non-steroidal Anti-inflammatory Drugs Market is analyzed across North America, Europe, Asia Pacific and LAMEA. North America emerged as the leading region in the Non-steroidal Anti-inflammatory Drugs Market with the maximum revenue share in 2021. Some of the key variables influencing the market’s growth include the existence of a sizable number of manufacturers and the strategic actions made by industry participants. In addition, it is predicted that the prevalence of arthritis and chronic pain will rise during the forecast period, accelerating growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., GlaxoSmithKline PLC, Bayer AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly And Company, Sanofi S.A., AstraZeneca PLC, Viatris, Inc., and Merck & Co., Inc.

Recent Strategies deployed in Non-steroidal Anti-inflammatory Drugs Market

Partnerships, Collaborations and Agreements:

May-2022: Dr. Reddy’s Laboratories formed a partnership with South Korea-based HK inno.N Corporation. Through this partnership, Tegoprazan would offer a new option for the treatment of gastric acid-related as well as mobility-impaired diseases like Erosive/Non-erosive Gastroesophageal Reflux Disease (GERD / NERD), Nonsteroidal anti-inflammatory drug-mediated ulcers, Gastric and Duodenal ulcers, and Helicobacter pylori eradication.

Product Launches and Product Expansions:

Aug-2021: Dr Reddy’s Laboratories introduced over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve, in the US market. This tablet is an over-the-counter non-steroidal anti-inflammatory drug (NSAID) for usage as a pain reliever and fever reducer.

May-2022: Dr. Reddy’s Laboratories released Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market. This product is a nonsteroidal anti-inflammatory drug (NSAID) demonstrated for the short-term management of moderately serious acute pain, which offers analgesia at the opioid stage and only as continuation treatment after intravenous or intramuscular dosing of ketorolac tromethamine, if necessary.

Approvals and Trails:

Feb-2022: Bayer received approval for Kerendia in the EU for adult people with chronic kidney disease related to type 2 diabetes. Kerendia is non-steroidal, which is a selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular (CV) results.

Jan-2022: Pfizer received approval from the United States (U.S.) Food and Drug Administration (FDA) for CIBINQO, an oral, once-daily, Janus kinase 1 (JAK1) inhibitor. CIBINQO is recommended for doses of 100 mg and 200 mg, along with the 200 mg dose being recommended for people for whom the medicine of 100 mg dose is less effective.

Dec-2020: GlaxoSmithKline got approval for BENLYSTA from the US Food and Drug Administration (FDA). This product is launched for the treatment of adult patients with active lupus nephritis (LN) who are getting standard therapy.

Sep-2020: Pfizer got the approval for XELJANZ from the United States (U.S.) Food and Drug Administration (FDA). This product is for the treatment of children and adolescents 2 years and elder with active polyarticular course juvenile idiopathic arthritis (pcJIA). In addition, the approval would make XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.

Mar-2020: GlaxoSmithKline received approval from the U.S. Food and Drug Administration (FDA) for Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief. This product would offer relief for various symptoms and is the first formulation, which integrates ibuprofen and acetaminophen, two powerful ingredients related to OTC pain relief that would work in multiple ways.

Feb-2020: GlaxoSmithKline got approval from the U.S. Food and Drug Administration (FDA) for Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever). This product is an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, elbow, wrist, ankle foot, or knee in adults.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration

• Oral

• Topical

• Others

By Distribution Channel

• Retail Pharmacy

• Hospital Pharmacy

• Online Pharmacy

By Disease Indication

• Arthritis

• Migraine

• Ophthalmic Diseases

• Others

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

• LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Dr. Reddy’s Laboratories Ltd.

• Pfizer, Inc.

• GlaxoSmithKline PLC

• Bayer AG

• Teva Pharmaceuticals Industries Ltd.

• Eli Lilly And Company

• Sanofi S.A.

• AstraZeneca PLC

• Viatris, Inc.

• Merck & Co., Inc.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free
Read the full report: https://www.reportlinker.com/p06315035/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001